Prosthetic Venous Valves Using ECM and Biologically Active Agents

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Conventional prosthetic venous valves face challenges such as in vivo calcification, cytotoxicity, and the need for systemic anti-coagulant drugs due to their material composition, and they often fail to effectively modulate blood flow, leading to complications like thrombosis and varicose veins.

Innovation Solution

The development of prosthetic venous valves with continuous conical shaped structural members and extracellular matrix (ECM) compositions derived from mammalian tissue, which include collagenous tissue from sources like bovine pericardium, and the integration of biologically active agents to enhance blood flow modulation and minimize calcification and cytotoxicity.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Strength

If conventional prosthetic venous valves are used, then structural support is provided, but in vivo calcification and cytotoxicity occur

Engineering Contradiction:

Improvestructural supportVSAvoidcalcification and cytotoxicity

Core Design Contradiction:

StrengthVSObject-affected harmful factors

Solution Approach 1:

The patent changes the material parameters by using biologically active agents and ECM compositions that alter the chemical and physical properties of the prosthetic valve, reducing calcification and cytotoxicity while maintaining structural support

Inventive Principle:

Principle #35Parameter changes

Solution Approach 2:

The patent employs composite materials combining ECM compositions with biologically active agents to create a prosthetic valve that provides structural support while minimizing harmful effects like calcification and cytotoxicity

Inventive Principle:

Principle #40Composite materials

2Reliability

If conventional prosthetic venous valves are used, then valve replacement is achieved, but blood flow modulation is insufficient leading to thrombosis and varicose veins

Engineering Contradiction:

Improvevalve replacementVSAvoidthrombosis and varicose veins

Core Design Contradiction:

ReliabilityVSObject-generated harmful factors

Solution Approach 1:

The patent modifies blood flow parameters by incorporating biologically active agents that improve endothelial function and blood flow dynamics, preventing thrombosis and varicose veins while maintaining valve replacement reliability

Inventive Principle:

Principle #35Parameter changes

Solution Approach 2:

The patent introduces biologically active agents as intermediaries that mediate between the prosthetic valve and blood flow, improving hemodynamic conditions and preventing pathological outcomes

Inventive Principle:

Principle #24Intermediary (Mediator)

3Ease of manufacture

If conventional materials are used in prosthetic venous valves, then manufacturing is simplified, but systemic anti-coagulant drugs are required

Engineering Contradiction:

Improvematerial compositionVSAvoidneed for anti-coagulant medications

Core Design Contradiction:

Ease of manufactureVSObject-affected harmful factors

Solution Approach 1:

The patent changes the material composition parameters by using ECM and biologically active agents that improve biocompatibility and reduce thrombogenicity, allowing simplified manufacturing without requiring systemic anti-coagulant drugs

Inventive Principle:

Principle #35Parameter changes

Data Source

PatentUS20240252319A1Prosthetic venous valves

Publication Date: 2024.08.01 CORVIVO CARDIOVASCULAR INC

AI summary

A conical shaped venous valve structure with a plurality of fluid flow modulating means that open and allow antegrade blood to be transmitted out of the valve structure and into and through an associated cardiovascular vessel when the valve structure is disposed in the cardiovascular vessel and the antegrade blood exhibits a positive pressure relative to the exterior pressure.